虚拟现实用于癌症疼痛的门诊治疗:试点剂量研究
Hunter Groninger1,2,3, Diana Violanti4, Mary Lynn McPherson5
1Medstar Washington Hospital Center, 110 Irving Street NW, Room 2A68, 20010, Washington, DC, USA. hunter.groninger@medstar.net.
概括
虚拟现实 (VR) 分心疗法显示,它有望减少慢性癌症疼痛. 这项试点研究表明,每天两次VR使用可能比每天一次使用更有效地控制疼痛.
科学领域:
- 在瘤学瘤学.
- 疼痛管理 疼痛管理
- 虚拟现实技术 虚拟现实技术
背景情况:
- 越来越多的证据支持虚拟现实 (VR) 缓解癌症疼痛.
- 关于在慢性癌症疼痛的门诊环境中重复使用VR的数据有限.
- 对癌症疼痛进行VR干预的最佳"剂量"尚未确立.
研究的目的:
- 研究重复使用虚拟现实 (VR) 对长期癌症疼痛严重程度在门诊环境中的影响.
- 探索VR干预的理想"剂量",以减轻癌症疼痛.
- 评估患者对VR用于疼痛管理的满意度.
主要方法:
- 进行了一项单臂无盲试验剂量研究.
- 参与者使用了Meta Quest 2 VR耳机,从每天10分钟的会议开始,逐渐达到每天两次,然后在3周内根据需要使用.
- 结果包括自我报告的疼痛评分 (SRPS),PROMIS疼痛干扰和对疼痛管理的满意度.
主要成果:
- 三十三名患有疼痛 (≥4/10) 的成年癌症患者参与了这项研究.
- 在为期3周的研究中,SRPS (p=0.04),疼痛干扰 (p=0.001) 和满意度 (p<0.001) 显著改善.
- 在参与者处方阿片类药物中,没有注意到突破性阿片类药物使用的显著变化.
结论:
- 与基线相比,每日虚拟现实 (VR) 分心治疗改善了慢性癌症疼痛.
- 每天两次VR剂量似乎比每天一次剂量更有益.
- 需要进行更大规模的研究来确认癌症疼痛中非药物VR干预的最佳剂量.
相关概念视频
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
370
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
370
01:25Analgesia and Pain Management
811
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
811
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
450
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
450
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
265
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
265
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
327
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
327